Cargando…

Decreased Heart Rate Variability in COVID-19

PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chengfen, Li, Jianguo, Wang, Zhiyong, Zhi, Yongle, Xu, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713139/
https://www.ncbi.nlm.nih.gov/pubmed/36471860
http://dx.doi.org/10.1007/s44231-022-00024-1
_version_ 1784841949096706048
author Yin, Chengfen
Li, Jianguo
Wang, Zhiyong
Zhi, Yongle
Xu, Lei
author_facet Yin, Chengfen
Li, Jianguo
Wang, Zhiyong
Zhi, Yongle
Xu, Lei
author_sort Yin, Chengfen
collection PubMed
description PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. This report aimed to highlight decreased heart rate variability (HRV) and cardiac injury caused by SARS-CoV-2. MATERIALS AND METHODS: We evaluated three COVID-19 patients who died. Patients’ data were collected from electronic medical records. We collected patient’s information, including baseline information, lab results, body temperature, heart rate (HR), clinical outcome and other related data. We calculated the HRV and the difference between the expected and actual heart rate changes as the body temperature increased. RESULTS: As of March 14, 2020, 3 (2.2%) of 136 patients with COVID-19 in Tianjin died in the early stage of the COVID-19 epidemic. The immediate cause of death for Case 1, Case 2, and Case 3 was cardiogenic shock, cardiac arrest and cardiac arrest, respectively. The HRV were substantially decreased in the whole course of all three cases. The actual increases in heart rate were 5 beats/min, 13 beats/min, and 4 beats/min, respectively, less than expected as their temperature increased. Troponin I and Creatine Kinase MB isoenzyme (CK-MB) were substantially increased only in Case 3, for whom the diagnosis of virus-related cardiac injury could not be made until day 7. In all three cases, decreased in HRV and HR changes occurred earlier than increases in cardiac biomarkers (e.g., troponin I and CK-MB). CONCLUSIONS: In conclusion, COVID-19 could affect HRV and counteract tachycardia in response to increases in body temperature. The decreases of HRV and HR changes happened earlier than the increases of myocardial markers (troponin I and CK-MB). It suggested the decreases of HRV and HR changes might help predict cardiac injury earlier than myocardial markers in COVID-19, thus its early identification might help improve patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s44231-022-00024-1.
format Online
Article
Text
id pubmed-9713139
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-97131392022-12-01 Decreased Heart Rate Variability in COVID-19 Yin, Chengfen Li, Jianguo Wang, Zhiyong Zhi, Yongle Xu, Lei Intensive Care Res Case Report PURPOSE: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. This report aimed to highlight decreased heart rate variability (HRV) and cardiac injury caused by SARS-CoV-2. MATERIALS AND METHODS: We evaluated three COVID-19 patients who died. Patients’ data were collected from electronic medical records. We collected patient’s information, including baseline information, lab results, body temperature, heart rate (HR), clinical outcome and other related data. We calculated the HRV and the difference between the expected and actual heart rate changes as the body temperature increased. RESULTS: As of March 14, 2020, 3 (2.2%) of 136 patients with COVID-19 in Tianjin died in the early stage of the COVID-19 epidemic. The immediate cause of death for Case 1, Case 2, and Case 3 was cardiogenic shock, cardiac arrest and cardiac arrest, respectively. The HRV were substantially decreased in the whole course of all three cases. The actual increases in heart rate were 5 beats/min, 13 beats/min, and 4 beats/min, respectively, less than expected as their temperature increased. Troponin I and Creatine Kinase MB isoenzyme (CK-MB) were substantially increased only in Case 3, for whom the diagnosis of virus-related cardiac injury could not be made until day 7. In all three cases, decreased in HRV and HR changes occurred earlier than increases in cardiac biomarkers (e.g., troponin I and CK-MB). CONCLUSIONS: In conclusion, COVID-19 could affect HRV and counteract tachycardia in response to increases in body temperature. The decreases of HRV and HR changes happened earlier than the increases of myocardial markers (troponin I and CK-MB). It suggested the decreases of HRV and HR changes might help predict cardiac injury earlier than myocardial markers in COVID-19, thus its early identification might help improve patient prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s44231-022-00024-1. Springer Netherlands 2022-12-01 2023 /pmc/articles/PMC9713139/ /pubmed/36471860 http://dx.doi.org/10.1007/s44231-022-00024-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Yin, Chengfen
Li, Jianguo
Wang, Zhiyong
Zhi, Yongle
Xu, Lei
Decreased Heart Rate Variability in COVID-19
title Decreased Heart Rate Variability in COVID-19
title_full Decreased Heart Rate Variability in COVID-19
title_fullStr Decreased Heart Rate Variability in COVID-19
title_full_unstemmed Decreased Heart Rate Variability in COVID-19
title_short Decreased Heart Rate Variability in COVID-19
title_sort decreased heart rate variability in covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713139/
https://www.ncbi.nlm.nih.gov/pubmed/36471860
http://dx.doi.org/10.1007/s44231-022-00024-1
work_keys_str_mv AT yinchengfen decreasedheartratevariabilityincovid19
AT lijianguo decreasedheartratevariabilityincovid19
AT wangzhiyong decreasedheartratevariabilityincovid19
AT zhiyongle decreasedheartratevariabilityincovid19
AT xulei decreasedheartratevariabilityincovid19